Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis.
Rheumatol Ther
February 2025
OPAL Rheumatology Ltd, Sydney, NSW, Australia.
Introduction: This study sought to describe treatment patterns, persistence, and effectiveness of upadacitinib (UPA) alone and compared to other Janus kinase inhibitors (JAKis) or tumor necrosis factor inhibitors (TNFis) in patients with rheumatoid arthritis (RA).
Methods: This retrospective, non-interventional study used the OPAL dataset, derived from electronic medical records. Patients initiated UPA (N = 2624), other JAKis (baricitinib and tofacitinib [N = 925]), or TNFis (adalimumab, etanercept, certolizumab, golimumab, infliximab [N = 3540]) between May 2020 and March 2023.
Prevalence and clinical features of interstitial lung disease in patients with psoriasis.
BMC Pulm Med
December 2024
Department of Dermatology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Background: Despite the autoimmune nature of psoriasis, the potential association between psoriasis and interstitial lung disease (ILD) remains underexplored. This study aimed to investigate the frequency and clinical features of ILD in patients with psoriasis and propose a new conceptual framework of "ILD associated with psoriasis".
Methods: A retrospective analysis of 117 patients with psoriasis was conducted, excluding those without chest imaging prior to methotrexate or biologic use and those with other comorbidities leading to ILD.
Survey of Dopamine Receptor D2 Antagonists as Retinal Antifibrotics.
J Ocul Pharmacol Ther
October 2024
Mayo Clinic, Department of Physiology and Biomedical Engineering, Rochester, Minnesota, USA.
To evaluate the potency and efficacy of a library of dopamine receptor D2 (D2R) antagonists in the mitigation of fibrotic activation in retinal pigment epithelial (RPE) cells. ARPE-19 cells were cultured and treated with methotrexate or 27 district D2R antagonists using a fibronectin deposition assay. The most potent compounds were then further assessed in assays measuring cellular proliferation, cellular migration, and profibrotic gene expression.
View Article and Find Full Text PDFPharmacological Therapy of Proliferative Vitreoretinopathy: Systematic Comparison of 36 Pharmacological Agents.
J Ocul Pharmacol Ther
March 2023
Department of Ophthalmology and University Hospital, LMU Munich, Munich, Germany.
Proliferative vitreoretinopathy (PVR) is currently treated surgically. Reliable pharmaceutical options would be desirable, and numerous drugs have been proposed. This study is intended to systematically compare and determine the most promising candidates for the treatment of PVR.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!